PubMed · 1982 · 12 citations · 0 references
PharmacyPharmaceutical AnalysisPharmacologyChromatographic AnalysisClinical PharmacologyTherapeutic Drug MonitoringAnalytical ChromatographyChromatographic Analysis Of PharmaceuticalsChromatographyDrug Safety MonitoringLiquid ChromatographyPsychiatric Drug MonitoringActive Metabolite MonitoringAnalytical Liquid ChromatographyBlood Drug AnalysisChromatographic Drug AnalysisDrug Metabolite MonitoringExtraction ColumnsInternal Standard AnalysisSerum Therapeutic Drug Monitoring
We describe a liquid-chromatographic procedure for amoxapine and 8-hydroxyamoxapine, its active metabolite, in serum. We used a mu-Bondapak C18 reversed-phase column and a mobile phase of acetonitrile/water (74/26 by vol) plus 26 microL of n-butylamine per liter. The compounds were measured at 254 nm, with 8-methoxyloxapine as internal standard. Necessary pre-analysis purification consisted of adsorbing the drug from serum onto extraction columns, eluting with 1-butanol/hexane (1/5 by vol), re-extracting into aqueous acid, and from that re-extracting again into the elution-solvent mixture. We prefer this procedure for monitoring both therapeutic and toxic concentrations of amoxapine, because parent drug and metabolite are measured separately.